The new International Consensus Classification (ICC) for Myeloid Neoplasms and Acute Leukemias was updated in 2022 by the World Health Organization (WHO). This includes the following conditions: essential thrombocythemia (ET), polycythemia vera (PV); primary myelofibrosis, MPN, unclassifiable (MPN-U); chronic myeloid leukemia (CML); chronic neutrophilic leukemia (CNL); and chronic eosinophilic leukemia. Nonetheless, there are three core subtypes of classical myeloproliferative neoplasms (MPN): essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (1). Effective treatment for this illness is frequently delayed by incorrect diagnoses. The current study assessed the contribution of routine blood tests to the precise diagnosis of MPN. Blood analysis was done on 101 adult MPN Sudanese patients in total. Eight standard blood parameters were analyzed using a Sysmex XE-2100TM machine. The values were compared across the subcategories, and a difference that was deemed statistically significant was defined as a value of P<0.05. The patients' median hemoglobin, platelet, and red blood cell counts were 523x103, 15.4 g/dl, and 5.7x109/l, respectively. There were noticeable variations between the subcategories. The current study demonstrated that the key component of accurately diagnosing MPNs according to WHO classifications is the evaluation of peripheral blood cells' blood routine parameters.